Barinthus Biotherapeutics Q2 EPS $(0.26) Beats $(0.30) Estimate
Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.30) by 13.33 percent. This is a 50 percent increase over losses of $(0.52) per
Barinthus lost less money than experts thought it would, which means the company is getting better at controlling costs. When a company doing research loses less money than expected, it shows the business is moving in a better direction.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.